The HER2 Extracellular Domain as a Prognostic and Predictive Factor in Breast Cancer
- 1 June 2002
- journal article
- review article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 3 (2) , 125-135
- https://doi.org/10.3816/cbc.2002.n.017
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinaseBiochemical Journal, 1999
- Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cellsOncogene, 1999
- The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cellsOncogene, 1997
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- Prognostic significance of serum c-erbB-2 protein in breast cancer patientsBreast Cancer Research and Treatment, 1996
- Serial serum c-erbB-2 levels in patients with breast carcinomaCancer, 1996
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogeneCell, 1988
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987